FDA — authorised 14 May 1998
- Application: NDA020912
- Marketing authorisation holder: MEDICURE
- Local brand name: AGGRASTAT
- Indication: INJECTABLE — INJECTION
- Status: approved
🇺🇸 tirofiban high-bolus dose regimen in United States
FDA authorised tirofiban high-bolus dose regimen on 14 May 1998
Marketing authorisations
FDA — authorised 14 May 1998
- Application: NDA020913
- Marketing authorisation holder: MEDICURE
- Local brand name: AGGRASTAT
- Indication: SOLUTION — INTRAVENOUS
- Status: approved
FDA
- Status: approved
tirofiban high-bolus dose regimen in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is tirofiban high-bolus dose regimen approved in United States?
Yes. FDA authorised it on 14 May 1998; FDA authorised it on 14 May 1998; FDA has authorised it.
Who is the marketing authorisation holder for tirofiban high-bolus dose regimen in United States?
MEDICURE holds the US marketing authorisation.